Galimedix Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Strategy
    • Management Team
    • Board of Directors
  • Products
  • Technology
    • Overview
    • MOA
    • Preclinical Experiments
    • Glaucoma Preclinical Data
    • AMD Preclinical Data
    • Trigger Effect
    • Superior Approach
    • Neurorestoration
  • Clinical Trials
  • References
  • News & Media
    • Press Releases
    • Presentations
    • Posters
    • Events
    • In the News
    • Videos
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Posters
  • Events
  • In the News
  • Videos

Galimedix Therapeutics to Participate in the 8th Annual Glaucoma 360 Conference

Jan 29, 2019

Galimedix Therapeutics Appoints Industry Veteran, Hermann Russ, M.D., Ph.D., Chief Scientific Officer

Dec 11, 2018

New In Vitro Study Demonstrates Galimedix Therapeutics’ Investigational Compound MRZ-99030 Neutralizes the Reproduction of Misfolded Amyloid-Beta, Thereby Potentially Reducing Synaptotoxic Effects

Nov 8, 2018
    • 1
    • 2
    © 2023 Galimedix Therapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap